Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Amgen Inc. et al v. Coherus Biosciences Inc.
Case Number:
1:17-cv-00546
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
November 30, 2020
Coherus Loses Bid To Shift Fees To Amgen In Patent Suit
A U.S. District Court judge in Delaware on Monday shot down Coherus BioSciences Inc.'s bid to shift legal fees to Amgen Inc. in its failed patent infringement suit against Coherus over a blockbuster anti-infection drug.
-
June 09, 2017
Coherus Assails Amgen's Neulasta Biosimilar Suit
Coherus Biosciences Inc. has told a Delaware federal court that its biosimilar application doesn’t infringe an Amgen Inc. patent covering anti-infection drug Neulasta and that Amgen’s infringement suit should be thrown out.
-
May 11, 2017
Amgen Patent Suit Targets Coherus' Neulasta Biosimilar
Amgen Inc. has sued biosimilar maker Coherus Biosciences Inc. in Delaware federal court for allegedly infringing a patent covering anti-infection medicine Neulasta, marking its latest court fight to protect the blockbuster biologic.